Navigation Links
Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
Date:7/27/2009

its patents and patent applications may be challenged, invalidated or circumvented by its competitors. Amgen depends on third parties for a significant portion of its manufacturing capacity for the supply of certain of its current and future products and limits on supply may constrain sales of certain of its current products and product candidate development. In addition, Amgen competes with other companies with respect to some of its marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for Amgen products are supplied by sole third-party suppliers.

The scientific information discussed in this news release related to Amgen's product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration (FDA) or other regulatory bodies, and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Only the FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Healthcare professionals should refer to and rely upon the labeling approved by the FDA or other regulatory bodies for the products, and not the information discussed in this news release.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from
'/>"/>

SOURCE Amgen; GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
2. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
3. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
4. Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
5. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. Amgen Announces Webcast of 2008 Third Quarter Financial Results
8. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
9. Call for Applications: The Amgen Award for Science Teaching Excellence
10. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
11. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  Discovery Laboratories, Inc. ... has received the second $1.0M tranche under a ... (SBIR) grant valued at up to $3.0 million ... KL4 surfactant as a potential medical countermeasure to ... Labs was awarded an initial $1.0 million under ...
(Date:7/29/2015)... 2015 Sanofi, a global ... second quarter of 2015. CEO Olivier Brandicourt ... performance in different businesses. Watch video ... Topics covered in the interview ... - Performance drivers - Diabetes ...
(Date:7/29/2015)... US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: ... progressing its ground-breaking technology platforms to Phase 1 clinical ... Company delivers the best value for shareholders. ... the Company currently had an extensive program of activities ... academic partnerships and initiatives, and he was working with ...
(Date:7/29/2015)... July 29, 2015  HealthSouth Corporation ... largest providers of post-acute healthcare services, offering both ... results of operations for the second quarter ended ... was characterized by strong volume growth in both ... EBITDA," said Jay Grinney, President and Chief Executive ...
Breaking Biology Technology:Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25
... ... ... PRXL ), a leading global biopharmaceutical services,organization, today announced the ... technology organization. By combining,ClinPhone with Perceptive Informatics, PAREXEL,s wholly-owned technology,subsidiary, ...
... p.m. ET Today -, SUNNYVALE, Calif., Aug. 14 ... its fourth quarter,and fiscal year ended June 30, 2008. The ... million, or $0.18 per share, compared to a net loss ... of fiscal 2007., Total operating expenses were $4.8 million ...
... aerospace and ocean engineering at Virginia Tech, has received ... Junior Faculty Award. The award will support Philen,s research ... material and structural systems that have the unique ability ... these innovative materials will lead to new and exciting ...
Cached Biology Technology:PAREXEL Closes the Acquisition of ClinPhone 2PAREXEL Closes the Acquisition of ClinPhone 3PAREXEL Closes the Acquisition of ClinPhone 4PAREXEL Closes the Acquisition of ClinPhone 5Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 2Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 3Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 4Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 5Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 6
(Date:7/7/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") a biometric ... revised version of one of its first 30 second commercials will ... New York , Chicago , ... metro areas.    , , , , ... the cards in your wallet and keep your identity secure. ...
(Date:7/2/2015)... 2015 Research and Markets( ... "Next Generation Biometrics Market by Application, Technology, Function & ... their offering. The next generation biometrics market ... a CAGR of 17.9% between 2015 and 2020 ... the market. Safran SA ( France ...
(Date:6/30/2015)... 30, 2015 To bolster its efforts and commitment ... announced today the addition of two new team members. ... advisor and David Raviv will act as head ... Corp.,s commitment to providing the most secure solutions for the ... co-founded Layer 7 Technologies, a provider of security and management ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... This release is available in French . ... and growing problem in hospitals and other health care facilities, ... developed in several decades. However, a large-scale, phase 3 trial ... antibiotic Fidaxomicin is superior to existing treatments, demonstrating a 45 ...
... Sputnik moment," President Obama emphasized the national need for ... State of the Union address last week: "We,ll invest ... technologyan investment that will strengthen our security, protect our ... President Obama specifically cited the need for research ...
... that five scientists with novel approaches to fighting cancer ... Innovation Award. The grant of $450,000 over three ... whose projects have the potential to significantly impact the ... The 2011 Damon Runyon-Rachleff Innovators are: Alexei ...
Cached Biology News:First new C. difficile drug in a generation superior to existing treatments: Researchers 2Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research 2Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research 3
Our Histology, Immunohistochemistry and tissue arrays services include samples processing, different type of staning, histollogical stains, image analysis, tissue arrays, immunohistochemistry, etc....
Mouse polyclonal antibody to GRID2 - glutamate receptor, ionotropic, delta 2...
... pLivSelect is a direct antibiotic-based selection system ... on colony survival, eliminating the need for ... process provides close to 100% accuracy in ... platform for robot colony picking. This cloning ...
Mouse polyclonal antibody raised against a partial recombinant KCTD13. NCBI Entrez Gene ID = 253980...
Biology Products: